Tokyo, Japan and Cambridge, UK, 31 October 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended 30 September 2025. The full report can be found here. Chris Cargill, President and CEO of Nxera, commented: “During the third quarter of 2025, we made strong progress in advancing our plans for obesity and metabolic diseases, an area of strategic focus where we see exceptional opport ...